




Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Ahrong Ham¹ · Min Hwan Kim¹ · Gun Min Kim¹ · Jee Hung Kim² · Jee Ye Kim³ · Hyung Seok Park³ · Seho Park³ · Young Up Cho³ · Byeong Woo Park³ · Seung Il Kim³ · Joohyuk Sohn¹ 

Published online: 14 July 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Breast Cancer Research and Treatment
<https://doi.org/10.1007/s10549-020-05750-y>

In the original publication of the article, under the Results section, subheading “Patient survival”, the second sentence that reads as “The 6-month PFS was 92.4%, 81.8%, and 93.3% and the 1-year PFS was 72.0%, 88.9%, and 78.9% in Groups 1–3, respectively.” should read as “The 6-month PFS was 82.8%, 75.0%, and 68.0% and the 1-year PFS was 77.0%, 62.0%, and 63.8% in Groups 1–3, respectively.”

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10549-020-05750-y>.

✉ Joohyuk Sohn
oncosohn@yuhs.ac

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea

² Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

³ Division of Breast Surgery, Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea